In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Myocardial constructive work is additive to volumetric response to cardiac resynchronization therapy in the prediction of mortality after CRT implantation

Session Prognostic impact of deformation imaging

Speaker Elena Galli

Congress : ESC Congress 2018

  • Topic : imaging
  • Sub-topic : Echocardiography: Systolic and Diastolic Function
  • Session type : Rapid Fire Abstracts
  • FP Number : 4915

Authors : E Galli (Rennes,FR), A Hubert (Rennes,FR), V Le Rolle (Rennes,FR), A Hernandez (RENNES,FR), O Smiseth (Oslo,NO), P Mabo (Rennes,FR), C Leclercq (Rennes,FR), E Donal (Rennes,FR)


E. Galli1 , A. Hubert1 , V. Le Rolle2 , A. Hernandez3 , O. Smiseth4 , P. Mabo1 , C. Leclercq1 , E. Donal1 , 1University Hospital of Rennes, Cardiology - Rennes - France , 2University of Rennes, Laboratoire Traitement du Signal et de l'Image, INSERM U-1099 - Rennes - France , 3INSERM, Laboratoire du traitement du Signal et de l'Image - RENNES - France , 4University of Oslo - Oslo - Norway ,

European Heart Journal ( 2018 ) 39 ( Supplement ), 1030

Background: Recent studies have shown that myocardial constructive work (CW) is an independent predictor of the volumetric response to cardiac resynchronization therapy (CRT).

Purpose of the study: To assess if CW is additive to volumetric CRT-response in the prediction of cardiac mortality in CRT-candidates.

Methods: 2D-standard and speckle-tracking echocardiography were performed in 166 CRT candidates (mean age: 66±10 years, males: 69%) before CRT implantation and at 6-month follow-up. Left ventricular (LV) CW was assessed by pressure-strain loops (PSLs). A reduction in LV end-systolic volume >15% at 6-month follow-up defined CRT-volumetric response and was observed in 48 (29%) patients.

Results: After a median 4-year FU (range: 1.3–5 years), cardiac death occurred in 14 patients (8%). CW and age were the only prognostic predictors of cardiac death (Table 1), independently from septal flash and CRT-volumetric response. At ROC curve analysis, CW≤888 mmHg% was the best cut-off to predict cardiac mortality (AUC 0.71, p=0.007). Among CRT responders, the presence of CW≤888 mmHg was associated with a dismal prognosis (log-rank test p=0.04). The concomitance of CW≤888 mmHg and absence of volumetric response to CRT identified patients with the worst prognosis (log-rank test p=0.001) (Figure 1)

Conclusions: Left ventricular CW allows the prediction of cardiac death in CRT candidates. A CW≤888 mmHg is associated with a increased cardiac mortality in both CRT responders and non-responders.

Table 1
Predictors of cardiac deathUnivariable analysisMultivariable analysis
HR95% CIp-valueHR95% CIp-value
Age, per year1.08(1.01–1.15)0.021.07(1.00–1.15)0.04
Male sex1.75(0.49–6.27)0.39
Ischaemic disease3.99(1.34–11.94)0.012.33(0.71–1.15)0.16
NYHA >21.39(0.46–4.24)0.56
QRS duration, per ms0.99(0.97–1.03)0.81
LVEF, per %0.99(0.92–1.08)0.89
LVEDV, per ml1.02(0.99–1.01)0.49
LVESV, per ml1.00(0.99–1.01)0.53
Septal flash0.19(0.06–0.62)0.0060.48(0.12–1.95)0.30
CW, per mmHg%0.99(0.99–1.00)0.040.99(0.99–1.00)0.04

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are